Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anika Therapeutics, Inc.

http://www.anikatherapeutics.com

Latest From Anika Therapeutics, Inc.

Drug Rebates, Impact On Premiums Must Be Disclosed Under COVID Stimulus Law

Medicare Part B payment loopholes also targeted in law, and Medicare Part D plans will need to offer real-time benefit tools for prescriber-patient decision making.

Reimbursement Pricing Strategies

Strides Targets $200m-$400m From Injectables

Strides has set a sales target of $200m-$400m for Stelis’ generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’ Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Strategy Biosimilars

Strides Targets $200-400m From Generic Injectables In Mid-Term

Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Biosimilars India

Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement

The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.

Orthopedics Surgical Procedures
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Medical Devices
    • Biomaterials
  • Other Names / Subsidiaries
    • Anika S.r.l.
    • Arthrosurface, Inc.
    • Fidia Advanced Biopolymers, s.r.l.
    • Parcus Medical, LLC
UsernamePublicRestriction

Register